Glaucoma Insights

Numerous studies have shown that adherence declines with more complex regimens of more than 1 or 2 bottles.

Mahmoud A. Khaimi, MD, developed a minimally invasive glaucoma surgery known as ab-interno canaloplasty as a treatment option between topical therapies and invasive surgery. The technique continues to prove its value.

The company’s IOPerfect combines artificial intelligence in a VR-like headset to allow tele-diagnosis and remote monitoring of glaucoma.

The 12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations.

TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.

Sight Sciences reveals real-world data that show the safety, efficacy, and durability of effect of its Omni Surgical System for use in a standalone procedure to reduce IOP and medication burden.

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.

According to iSTAR Medical, the STAR-V study will investigate the device in 350 patients with primary open angle glaucoma.

Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME.